Cholesterol absorption inhibitor ezetimibe: Risk– benefits and role in treating dyslipidemias

Shizuya Yamashita, Daisaku Masuda, Akifumi Matsuyama

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Ezetimibe, a novel lipid-lowering compound, selectively inhibits intestinal cholesterol absorption by binding to Niemann-Pick C1-Like 1 (NPC1L1). Ezetimibe reduces the hepatic influx of cholesterol via chylomicron remnants, enhances the hepatic expression of low-density lipoproteins (LDL) receptor, and thus reducing LDL-cholesterol (LDL-C) levels. Ezetimibe also attenuates the development of atherosclerosis in various animal models. The administration of ezetimibe decreases the fasting levels of LDL-C in patients with primary hypercholesterolemia as well as plant sterols in patients with sitosterolemia. A significantly greater reduction in LDL-C levels is achieved in patients treated with ezetimibe plus statin combination compared with statin monotherapy. Ezetimibe was reported to decrease fasting triglycerides (TG) levels as well as postprandial TG-rich lipoprotein and remnants significantly in patients with combined hyperlipidemia and those with hypertriglyceridemia (TG ≥ 150 mg/dl); however, its underlying mechanism of action on TG-rich lipoprotein metabolism has not yet been elucidated. Ezetimibe administration can attenuate postprandial hyperlipidemia by reducing the production of chylomicrons (CMs) from the small intestines and decreasing the absorption of free fatty acids (FFA). More recently, ezetimibe has been reported to attenuate nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) in animal models and humans. Since the influx of chylomicron remnants and FFA into the liver is decreased by ezetimibe, it is plausible that it may attenuate hepatic lipid deposition. The antiatherosclerotic effects of ezetimibe have been demonstrated in a variety of animal models and more recently in some clinical trials. In the recent Study of Heart and Renal Protection (SHARP) Trial, the combination of simvastatin and ezetimibe was shown to be effective for major atherosclerotic events in patients with chronic kidney disease. Taken together, ezetimibe may possess additional pleiotropic roles in addition to lipid-lowering effects.

Original languageEnglish
Title of host publicationDyslipidemias
Subtitle of host publicationPathophysiology, Evaluation and Management
PublisherHumana Press Inc.
Pages465-481
Number of pages17
ISBN (Electronic)9781607614241
ISBN (Print)9781607614234
DOIs
Publication statusPublished - 01-01-2015

Fingerprint

Anticholesteremic Agents
Dyslipidemias
Triglycerides
Chylomicron Remnants
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Animal Models
Liver
Hyperlipidemias
Lipids
LDL Lipoproteins
Nonesterified Fatty Acids
Lipoproteins
Fasting
Ezetimibe
Cholesterol
Chylomicrons
Phytosterols
LDL Receptors
Hypertriglyceridemia
Intestinal Absorption

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Yamashita, S., Masuda, D., & Matsuyama, A. (2015). Cholesterol absorption inhibitor ezetimibe: Risk– benefits and role in treating dyslipidemias. In Dyslipidemias: Pathophysiology, Evaluation and Management (pp. 465-481). Humana Press Inc.. https://doi.org/10.1007/978-1-60761-424-1_28
Yamashita, Shizuya ; Masuda, Daisaku ; Matsuyama, Akifumi. / Cholesterol absorption inhibitor ezetimibe : Risk– benefits and role in treating dyslipidemias. Dyslipidemias: Pathophysiology, Evaluation and Management. Humana Press Inc., 2015. pp. 465-481
@inbook{c2ede8abd2524589804f2f2a5a5b0b09,
title = "Cholesterol absorption inhibitor ezetimibe: Risk– benefits and role in treating dyslipidemias",
abstract = "Ezetimibe, a novel lipid-lowering compound, selectively inhibits intestinal cholesterol absorption by binding to Niemann-Pick C1-Like 1 (NPC1L1). Ezetimibe reduces the hepatic influx of cholesterol via chylomicron remnants, enhances the hepatic expression of low-density lipoproteins (LDL) receptor, and thus reducing LDL-cholesterol (LDL-C) levels. Ezetimibe also attenuates the development of atherosclerosis in various animal models. The administration of ezetimibe decreases the fasting levels of LDL-C in patients with primary hypercholesterolemia as well as plant sterols in patients with sitosterolemia. A significantly greater reduction in LDL-C levels is achieved in patients treated with ezetimibe plus statin combination compared with statin monotherapy. Ezetimibe was reported to decrease fasting triglycerides (TG) levels as well as postprandial TG-rich lipoprotein and remnants significantly in patients with combined hyperlipidemia and those with hypertriglyceridemia (TG ≥ 150 mg/dl); however, its underlying mechanism of action on TG-rich lipoprotein metabolism has not yet been elucidated. Ezetimibe administration can attenuate postprandial hyperlipidemia by reducing the production of chylomicrons (CMs) from the small intestines and decreasing the absorption of free fatty acids (FFA). More recently, ezetimibe has been reported to attenuate nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) in animal models and humans. Since the influx of chylomicron remnants and FFA into the liver is decreased by ezetimibe, it is plausible that it may attenuate hepatic lipid deposition. The antiatherosclerotic effects of ezetimibe have been demonstrated in a variety of animal models and more recently in some clinical trials. In the recent Study of Heart and Renal Protection (SHARP) Trial, the combination of simvastatin and ezetimibe was shown to be effective for major atherosclerotic events in patients with chronic kidney disease. Taken together, ezetimibe may possess additional pleiotropic roles in addition to lipid-lowering effects.",
author = "Shizuya Yamashita and Daisaku Masuda and Akifumi Matsuyama",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-1-60761-424-1_28",
language = "English",
isbn = "9781607614234",
pages = "465--481",
booktitle = "Dyslipidemias",
publisher = "Humana Press Inc.",

}

Yamashita, S, Masuda, D & Matsuyama, A 2015, Cholesterol absorption inhibitor ezetimibe: Risk– benefits and role in treating dyslipidemias. in Dyslipidemias: Pathophysiology, Evaluation and Management. Humana Press Inc., pp. 465-481. https://doi.org/10.1007/978-1-60761-424-1_28

Cholesterol absorption inhibitor ezetimibe : Risk– benefits and role in treating dyslipidemias. / Yamashita, Shizuya; Masuda, Daisaku; Matsuyama, Akifumi.

Dyslipidemias: Pathophysiology, Evaluation and Management. Humana Press Inc., 2015. p. 465-481.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Cholesterol absorption inhibitor ezetimibe

T2 - Risk– benefits and role in treating dyslipidemias

AU - Yamashita, Shizuya

AU - Masuda, Daisaku

AU - Matsuyama, Akifumi

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Ezetimibe, a novel lipid-lowering compound, selectively inhibits intestinal cholesterol absorption by binding to Niemann-Pick C1-Like 1 (NPC1L1). Ezetimibe reduces the hepatic influx of cholesterol via chylomicron remnants, enhances the hepatic expression of low-density lipoproteins (LDL) receptor, and thus reducing LDL-cholesterol (LDL-C) levels. Ezetimibe also attenuates the development of atherosclerosis in various animal models. The administration of ezetimibe decreases the fasting levels of LDL-C in patients with primary hypercholesterolemia as well as plant sterols in patients with sitosterolemia. A significantly greater reduction in LDL-C levels is achieved in patients treated with ezetimibe plus statin combination compared with statin monotherapy. Ezetimibe was reported to decrease fasting triglycerides (TG) levels as well as postprandial TG-rich lipoprotein and remnants significantly in patients with combined hyperlipidemia and those with hypertriglyceridemia (TG ≥ 150 mg/dl); however, its underlying mechanism of action on TG-rich lipoprotein metabolism has not yet been elucidated. Ezetimibe administration can attenuate postprandial hyperlipidemia by reducing the production of chylomicrons (CMs) from the small intestines and decreasing the absorption of free fatty acids (FFA). More recently, ezetimibe has been reported to attenuate nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) in animal models and humans. Since the influx of chylomicron remnants and FFA into the liver is decreased by ezetimibe, it is plausible that it may attenuate hepatic lipid deposition. The antiatherosclerotic effects of ezetimibe have been demonstrated in a variety of animal models and more recently in some clinical trials. In the recent Study of Heart and Renal Protection (SHARP) Trial, the combination of simvastatin and ezetimibe was shown to be effective for major atherosclerotic events in patients with chronic kidney disease. Taken together, ezetimibe may possess additional pleiotropic roles in addition to lipid-lowering effects.

AB - Ezetimibe, a novel lipid-lowering compound, selectively inhibits intestinal cholesterol absorption by binding to Niemann-Pick C1-Like 1 (NPC1L1). Ezetimibe reduces the hepatic influx of cholesterol via chylomicron remnants, enhances the hepatic expression of low-density lipoproteins (LDL) receptor, and thus reducing LDL-cholesterol (LDL-C) levels. Ezetimibe also attenuates the development of atherosclerosis in various animal models. The administration of ezetimibe decreases the fasting levels of LDL-C in patients with primary hypercholesterolemia as well as plant sterols in patients with sitosterolemia. A significantly greater reduction in LDL-C levels is achieved in patients treated with ezetimibe plus statin combination compared with statin monotherapy. Ezetimibe was reported to decrease fasting triglycerides (TG) levels as well as postprandial TG-rich lipoprotein and remnants significantly in patients with combined hyperlipidemia and those with hypertriglyceridemia (TG ≥ 150 mg/dl); however, its underlying mechanism of action on TG-rich lipoprotein metabolism has not yet been elucidated. Ezetimibe administration can attenuate postprandial hyperlipidemia by reducing the production of chylomicrons (CMs) from the small intestines and decreasing the absorption of free fatty acids (FFA). More recently, ezetimibe has been reported to attenuate nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) in animal models and humans. Since the influx of chylomicron remnants and FFA into the liver is decreased by ezetimibe, it is plausible that it may attenuate hepatic lipid deposition. The antiatherosclerotic effects of ezetimibe have been demonstrated in a variety of animal models and more recently in some clinical trials. In the recent Study of Heart and Renal Protection (SHARP) Trial, the combination of simvastatin and ezetimibe was shown to be effective for major atherosclerotic events in patients with chronic kidney disease. Taken together, ezetimibe may possess additional pleiotropic roles in addition to lipid-lowering effects.

UR - http://www.scopus.com/inward/record.url?scp=84956742034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956742034&partnerID=8YFLogxK

U2 - 10.1007/978-1-60761-424-1_28

DO - 10.1007/978-1-60761-424-1_28

M3 - Chapter

AN - SCOPUS:84956742034

SN - 9781607614234

SP - 465

EP - 481

BT - Dyslipidemias

PB - Humana Press Inc.

ER -

Yamashita S, Masuda D, Matsuyama A. Cholesterol absorption inhibitor ezetimibe: Risk– benefits and role in treating dyslipidemias. In Dyslipidemias: Pathophysiology, Evaluation and Management. Humana Press Inc. 2015. p. 465-481 https://doi.org/10.1007/978-1-60761-424-1_28